Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T J Allen

Showing results (91-100 of 97) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 97 results.
Kidney International|October 1, 1993
Long-term glycemic control and the rate of progression of early diabetic kidney diseaseR E Gilbert, C Tsalamandris, L A Bach, et al.
Diabetologia|October 29, 2009
The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout miceA M D Watson, J Li, C Schumacher, et al.
Diabetologia|October 23, 2009
Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-beta in a murine diabetic model of atherosclerosisY Pham, Y Tu, T Wu, et al.
Diabetologia|January 25, 2013
Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetesA M D Watson, M Olukman, C Koulis, et al.
Diabetologia|December 4, 2009
Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetesA Koïtka, Z Cao, P Koh, et al.
Diabetologia|December 17, 2010
Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout miceA M D Watson, A Soro-Paavonen, K Sheehy, et al.
Diabetologia|July 16, 2010
Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptorK C Sourris, A L Morley, A Koitka, et al.
Pageof 10

Showing results (91-100 of 97) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 97 results.
Kidney International|October 1, 1993
Long-term glycemic control and the rate of progression of early diabetic kidney diseaseR E Gilbert, C Tsalamandris, L A Bach, et al.
Diabetologia|October 29, 2009
The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout miceA M D Watson, J Li, C Schumacher, et al.
Diabetologia|October 23, 2009
Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-beta in a murine diabetic model of atherosclerosisY Pham, Y Tu, T Wu, et al.
Diabetologia|January 25, 2013
Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetesA M D Watson, M Olukman, C Koulis, et al.
Diabetologia|December 4, 2009
Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetesA Koïtka, Z Cao, P Koh, et al.
Diabetologia|December 17, 2010
Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout miceA M D Watson, A Soro-Paavonen, K Sheehy, et al.
Diabetologia|July 16, 2010
Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptorK C Sourris, A L Morley, A Koitka, et al.
Pageof 10